Additionally, the 36-month beta value for CRBP is 2.44. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CRBP is 10.38M and currently, short sellers hold a 4.58% ratio of that float. The average trading volume of CRBP on April 18, 2024 was 958.19K shares.
CRBP) stock’s latest price update
The stock price of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has dropped by -9.63 compared to previous close of 41.12. Despite this, the company has seen a fall of -2.60% in its stock price over the last five trading days. 24/7 Wall Street reported 2024-03-17 that The Oracle of Omaha has once more bolstered his stake in a media giant’s tracking stocks.
CRBP’s Market Performance
CRBP’s stock has fallen by -2.60% in the past week, with a monthly drop of -10.72% and a quarterly rise of 504.23%. The volatility ratio for the week is 9.11% while the volatility levels for the last 30 days are 9.46% for Corbus Pharmaceuticals Holdings Inc The simple moving average for the past 20 days is -4.10% for CRBP’s stock, with a 169.31% simple moving average for the past 200 days.
Analysts’ Opinion of CRBP
Many brokerage firms have already submitted their reports for CRBP stocks, with Jefferies repeating the rating for CRBP by listing it as a “Buy.” The predicted price for CRBP in the upcoming period, according to Jefferies is $46 based on the research report published on March 06, 2024 of the current year 2024.
ROTH Capital, on the other hand, stated in their research note that they expect to see CRBP reach a price target of $3, previously predicting the price at $40. The rating they have provided for CRBP stocks is “Neutral” according to the report published on September 08th, 2020.
CRBP Trading at 8.77% from the 50-Day Moving Average
After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.49% of loss for the given period.
Volatility was left at 9.46%, however, over the last 30 days, the volatility rate increased by 9.11%, as shares sank -13.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +42.05% upper at present.
During the last 5 trading sessions, CRBP fell by -2.60%, which changed the moving average for the period of 200-days by +373.98% in comparison to the 20-day moving average, which settled at $38.47. In addition, Corbus Pharmaceuticals Holdings Inc saw 515.23% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBP starting from Cormorant Asset Management, LP, who purchase 300,000 shares at the price of $44.38 back on Mar 08 ’24. After this action, Cormorant Asset Management, LP now owns 2,025,000 shares of Corbus Pharmaceuticals Holdings Inc, valued at $13,314,193 using the latest closing price.
Cormorant Asset Management, LP, the 10% Owner of Corbus Pharmaceuticals Holdings Inc, purchase 250,000 shares at $40.05 during a trade that took place back on Mar 07 ’24, which means that Cormorant Asset Management, LP is holding 1,725,000 shares at $10,013,367 based on the most recent closing price.
Stock Fundamentals for CRBP
Current profitability levels for the company are sitting at:
- -33.4 for the present operating margin
- 0.39 for the gross margin
The net margin for Corbus Pharmaceuticals Holdings Inc stands at -33.74. The total capital return value is set at 12.45. Equity return is now at value -341.98, with -94.31 for asset returns.
Based on Corbus Pharmaceuticals Holdings Inc (CRBP), the company’s capital structure generated 1.49 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at -3.02. The interest coverage ratio of the stock is -2689.9.
Currently, EBITDA for the company is -44.44 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of 294.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
In conclusion, Corbus Pharmaceuticals Holdings Inc (CRBP) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
